Douglas A. Treco's most recent trade in CRISPR Therapeutics AG was a trade of 20,000 Common Shares done at an average price of $57.0 . Disclosure was reported to the exchange on Aug. 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Douglas A. Treco | Director | Purchase of securities on an exchange or from another person at price $ 57.03 per share. | 06 Aug 2025 | 20,000 | 22,000 (0%) | 0% | 57.0 | 1,140,600 | Common Shares |
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO & Chairman | Grant, award, or other acquisition of securities at price $ 0.74 per share. | 25 Jun 2025 | 2,815 | 43,861 | - | 0.7 | 2,083 | Common Stock |
| CRISPR Therapeutics AG | Douglas A. Treco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO & Chairman | 01 Apr 2025 | 25,000 | 50,000 | - | - | Restricted Stock Units | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO & Chairman | 01 Apr 2025 | 25,000 | 49,865 | - | - | Common Stock | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO & Chairman | 01 Apr 2025 | 8,819 | 41,046 | - | 0.9 | 7,849 | Common Stock | |
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 11 Mar 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 11 Mar 2025 | 100,000 | 100,000 | - | - | Restricted Stock Units | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 30 Sep 2024 | 1,710 | 22,375 | - | 4.5 | 7,610 | Common Stock | |
| CRISPR Therapeutics AG | Douglas A. Treco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 01 Apr 2024 | 25,000 | 28,188 | - | - | Common Stock | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 01 Apr 2024 | 25,000 | 75,000 | - | - | Restricted Stock Units | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 01 Apr 2024 | 7,523 | 20,665 | - | 6.9 | 52,210 | Common Stock | |
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 13 Mar 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 01 Apr 2023 | 800,000 | 800,000 | - | - | Stock option (right to buy) | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director, CEO | 01 Apr 2023 | 100,000 | 100,000 | - | - | Restricted stock units | ||
| Inozyme Pharma Inc | Douglas A. Treco | Director | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| CRISPR Therapeutics AG | Douglas A. Treco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Douglas A. Treco | Director | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| CRISPR Therapeutics AG | Douglas A. Treco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |